Clayton Crolius - 09 Feb 2026 Form 4 Insider Report for DNA X, Inc. (SONM)

Reporting relationship: Chief Financial Officer
Issuer ticker: SONM
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2026, 20:55:33 UTC
Prior SEC filing: 25 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Clay Crolius

Key filing fact

Clayton Crolius filed Form 4 for DNA X, Inc. (SONM) on 10 Feb 2026.

Key facts

This page summarizes Clayton Crolius's Form 4 filing for DNA X, Inc. (SONM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Feb 2026, 20:55.

Change

Previous filing in this sequence was filed on 25 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001937013 Primary reporting owner

Crolius Clayton

Relationship: Chief Financial Officer
Address: C/O DNA X, INC., 4445 EASTGATE MALL, SUITE 200, SAN DIEGO
Signature: /s/ Clay Crolius
Signature date: 10 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SONM transaction

Common Stock

Award

Transaction value: $0
Shares: +35,000
Change %: +2036%
Price: $0.000000
Shares after: 36,719
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Footnote F2

Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units.

Footnote F3

The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.